

Journal of Visualized Experiments

Monitoring neuronal survival via longitudinal fluorescence microscopy

--Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE59036R1
Full Title:	Monitoring neuronal survival via longitudinal fluorescence microscopy
Keywords:	Cell death Neurodegeneration Fluorescence microscopy Automation Transfection Survival analysis
Corresponding Author:	Sami Barmada University of Michigan Ann Arbor, MI UNITED STATES
Corresponding Author's Institution:	University of Michigan
Corresponding Author E-Mail:	sbarmada@umich.edu
Order of Authors:	Kaitlin Weskamp Nathaniel Safren Roberto Miguez Sami Barmada
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Ann Arbor, MI, USA



Sami Barmada, MD, PhD
 Assistant Professor
 5015 BSRB, 109 Zina Pitcher Pl
 Ann Arbor, MI 48109-2200
 734-763-2624, sbarmada@umich.edu

October 9, 2018

Dear Editor,

Please find enclosed a revised manuscript entitled “Monitoring neuronal survival via single-cell longitudinal fluorescence microscopy” for consideration of publication in *The Journal of Visualized Experimentation (JoVE)*. This resubmission (previously titled “Monitoring neuronal survival via longitudinal fluorescence microscopy”) is in response to an invitation from Ronald Myers, Science Editor at *JoVE*. In this manuscript, we provide detailed information on automated or longitudinal fluorescence microscopy, complete with a step-by-step protocol for conducting experiments involving automated microscopy. We also provide sample worksheets and scripts for data processing and analysis to facilitate the adoption of this method where needed.

In response to comments and suggestions from the editor and reviewers, we have made several revisions to the manuscript:

- The title has been changed to “Monitoring neuronal survival via single-cell longitudinal fluorescence microscopy” to reflect the unique ability of this technique to monitor individual cells over time.
- We expanded the introduction and revised Figure 1 to better illustrate the concept of longitudinal fluorescence microscopy.
- We added new references describing conventional methods for determining cell death and criteria for judging time of death.
- We discuss alternative possibilities to cell death, including the movement of cells and the delayed appearance of cells over the experimental time course.
- All auxiliary verbs have been removed and replaced by imperatives where possible.
- All references to company names or trademarks have been removed from the text.
- An appropriate ethics statement is now included within the text.
- The protocol now includes references to in-depth protocols where necessary.
- The protocol is now more streamlined, with additional information provided within notes or moved to the Representative Results and Discussion sections.
- The Discussion section now includes a list of critical steps that can be modified for individual applications.
- The table of essential supplies has been modified to include company names where needed.

We are confident that these revisions have strengthened the manuscript and clarified the protocol, ultimately making it easier for readers to follow and recapitulate. No portion of this manuscript or the attached documents have appeared in print or been submitted for publication elsewhere. Thank you for your consideration of this manuscript.

Please do not hesitate to contact me with questions or concerns.

Sincerely,

Sami Barmada, MD, PhD
 Assistant Professor of Neurology and
 Angela Dobson and Lyndon Welch Research Professor of Neurology

TITLE:

Monitoring Neuronal Survival *Via* Single-cell Longitudinal Fluorescence Microscopy

AUTHORS AND AFFILIATIONS:

Kaitlin Weskamp^{1,2*}, Nathaniel Safren^{1*}, Roberto Miguez¹, Sami Barmada^{1,2}

¹Department of Neurology, University of Michigan School of Medicine, Ann Arbor, MI, USA

²Neuroscience Graduate Program, University of Michigan School of Medicine, Ann Arbor, MI, USA

*These authors contributed equally.

Corresponding Author:

Sami Barmada (sbarmada@umich.edu)

Email Addresses of Co-authors:

Kaitlin Weskamp (kweskamp@umich.edu)

Nathaniel Safren (Nathaniel.Safren@gmail.com)

Roberto Miguez (rmiguez@umich.edu)

KEYWORDS:

Cell death, neurodegeneration, fluorescence microscopy, automation, transfection, survival analysis

SUMMARY:

Here, we present a protocol to monitor survival on a single-cell basis and identify variables that significantly predict cell death.

ABSTRACT:

Standard cytotoxicity assays, which require the collection of lysates or fixed cells at multiple time points, have limited sensitivity and capacity to assess factors that influence neuronal fate. These assays require the observation of separate populations of cells at discrete time points. As a result, individual cells cannot be followed prospectively over time, severely limiting the ability to discriminate whether subcellular events, such as puncta formation or protein mislocalization, are pathogenic drivers of disease, homeostatic responses, or merely coincidental phenomena. Single-cell longitudinal microscopy overcomes these limitations, allowing the researcher to determine differences in survival between populations and draw causal relationships with enhanced sensitivity. This video guide will outline a representative workflow for experiments measuring single-cell survival of rat primary cortical neurons expressing a fluorescent protein marker. The viewer will learn how to achieve high-efficiency transfections, collect and process images enabling the prospective tracking of individual cells, and compare the relative survival of neuronal populations using Cox proportional hazards analysis.

INTRODUCTION:

Abnormal cell death is a driving factor in many diseases, including cancer, neurodegeneration, and stroke¹. Robust and sensitive assays for cell death are essential to the characterization of these disorders, as well as the development of therapeutic strategies for extending or reducing cellular survival. There are currently dozens of techniques for measuring cell death, either directly or through surrogate markers². For example, cell death can be assessed visually with the help of vital dyes that selectively stain dead or living cells³, or by monitoring the appearance of specific phospholipids on the plasma membrane⁴⁻⁶. Measurements of intracellular components or cellular metabolites released into the media upon cellular dissolution can also be used as proxies for cell death^{7,8}. Alternatively, cellular viability can be approximated by assessing metabolic activity^{9,10}. Though these methods provide rapid means of assessing cell survival, they are not without caveats. Each technique observes the culture as a single population, rendering it impossible to distinguish between individual cells and their unique rates of survival. Furthermore, such population-based assays are unable to measure factors that may be important for cell death, including cellular morphology, protein expression, or localization. In many cases, these assays are limited to discrete time points, and do not allow for the continuous observation of cells over time.

In contrast, longitudinal fluorescence microscopy is a highly flexible methodology that directly and continuously monitors the risk of death on a single-cell basis¹¹. In brief, longitudinal fluorescence microscopy enables thousands of individual cells to be tracked at regular intervals for extended periods of time, allowing precise determinations of cell death and the factors that enhance or suppress cell death. At its base, the method involves the transient transfection or transduction of cells with vectors encoding fluorescent proteins. A unique fiduciary is then established, and the position of each transfected cell in relation to this landmark allows the user to image and track individual cells over the course of hours, days, or weeks. When these images are viewed sequentially, cell death is marked by characteristic changes in fluorescence, morphology, and fragmentation of the cell body, enabling the assignment of a time of death for each cell. The calculated rate of death, determined by the hazard function, can then be quantitatively compared between conditions, or related to select cellular characteristics using univariate or multivariate Cox proportional hazards analysis¹². Together, these approaches enable the accurate and objective discrimination of rates of cell death among cellular populations, and the identification of variables that significantly predict cell death and/or survival (**Figure 1**).

Although this method can be used to monitor survival in any post-mitotic cell type in a variety of plating formats, this protocol will describe conditions for transfecting and imaging rat cortical neurons cultured in a 96-well plate.

PROTOCOL:

All vertebrate animal work was approved by the Committee on the Use and Care of Animals at the University of Michigan (protocol # PRO00007096). Experiments are carefully planned to minimize the number of animals sacrificed. Pregnant female wild-type (WT), non-transgenic Long Evans rats (*Rattus norvegicus*) are housed singly in chambers equipped with environmental enrichment, and cared for by the Unit for Laboratory Animal Medicine (ULAM)

at the University of Michigan, in accordance with the NIH-supported Guide for the Care and Use of Laboratory Animals. All rats were kept in routine housing for as little time as possible prior to euthanasia, consistent with the recommendations of the Guidelines on Euthanasia of the American Veterinary Medical Association and the University of Michigan Methods of Euthanasia by Species Guidelines.

1. Material Preparation

1.1. Dissect cortical neurons from embryonic day 19 - 20 rat pups and culture rat cortical neurons at 0.5×10^6 cells per milliliter on poly-D-lysine coated plates for 4 days *in vitro*, as described previously¹³⁻¹⁹.

1.2. Prepare the plasmid DNA of interest following the steps outlined by an endotoxin-free plasmid DNA isolation kit (see **Table of Materials**). Quantify the resultant DNA using a spectrophotometer.

1.3. On *in vitro* day 4 (DIV4), aliquot, filter sterilize, and incubate the following media at 37 °C: 6 mL reduced serum media (RSM; *e.g.*, OptiMEM), 25 mL neuronal basal media (NBM), 40 mL NBKY (NBM + 1 mM kynurenic acid + 10 mM MgCl₂, adjusted to a pH of 7.4), 10 mL NBC (NBM + 1x neuronal cell culture supplement + 1x L-glutamine supplement + 1x Pen Strep).

NOTE: Volumes listed are sufficient for transfecting one 96-well plate. Refer to the **Table of Materials** for specific reagents.

2. Transfection of Rat Cortical Neurons

2.1. Modify the provided *Example transfection sheet* (see **Supplemental File 1**) by adjusting the plate type, plate map, number of DNAs, DNA concentration, and number of wells (green boxes).

NOTE: The total DNA sums to 0.2 µg per well, regardless of whether one (*e.g.*, DNA A) or multiple (*e.g.*, DNA B and C) DNA constructs are added to each well.

2.2. Working from the spreadsheet, combine the appropriate amount of RSM and DNA in one tube. Combine the appropriate amount of RSM and transfection reagent (*e.g.*, Lipofectamine) in a separate tube.

2.3. Incubate at room temperature (RT) for 5 min.

2.4. Combine the DNA and transfection reagent RSM mixtures and incubate at RT for 20 min.

2.5. During this incubation step, use a multichannel pipette and sterile plastic troughs to wash cells 2x with 100 µL per well of NBM. Reserve the conditioned media (CM) and store at 37 °C. For this and following steps, take care to minimize the amount of time neurons are exposed to air.

2.6. Remove the NBM media and replace with 100 μ L per well of NBKY.

2.7. After 20 minutes have passed, add 50 μ L of the transfection reagent/DNA mixture dropwise to each well.

2.8. Incubate cells with the transfection reagent/DNA complexes for 20 min at 37 °C.

2.9. Rinse 2x with NBKY and replace with 100 μ L of CM and 100 μ L of NBC per well.

2.10. Successfully transfected cells should be visible by fluorescence microscopy within 16 - 24 h of transfection. To gauge efficiency, use a fluorescent microscope to check the transfection after overnight incubation at 37 °C.

NOTE: This technique results in an overall transfection efficiency of 5 to 10%.

3. Imaging

3.1. Place the plate on a fluorescent microscope with a motorized stage, and establish a fiduciary (*e.g.*, a mark on the bottom of the plate) that will allow the user to align the plate each time it is imaged. Save an image of this fiduciary for reference.

3.2. Navigate to a field of interest and note the x-y coordinates relative to the fiduciary.

3.3. Focus on transfected cells expressing a fluorescent label.

3.4. Take fluorescent images in the appropriate channel or channels (*e.g.*, red fluorescent protein [RFP], green fluorescent protein [GFP], 4',6-diamidino-2-phenylindole [DAPI]), either manually or in an automated manner. By taking several images at regularly-spaced intervals, a montage of the well can be assembled during image processing (see step 4).

NOTE: The spacing depends on several factors, including magnification, the optics of the microscope, and the detector size. In general, the optical spacing between adjacent images will be between 90 - 95% of the size of each individual image, to allow for a small degree of image overlap and feature alignment.

3.5. Repeat this process as often as required, aligning to the original fiduciary each time. For survival analysis, imaging takes place every 6 - 24 h, depending on the cell type and the purpose of the experiment.

4. Image Processing

NOTE: Following image acquisition, a series of processing steps are required prior to image analysis. These include, but are not limited to, stitching, stacking, and background subtraction

(**Figure 1**). The goal of these steps is to produce an image stack, or time series, in which cells are clearly discernible from their background and easy to follow over multiple time points. A dedicated FIJI macro (*Image_Processing.ijm*, see **Supplemental File 2**), performs basic stitching, stacking, and background subtraction. An explanation of each step and the parameters to consider when performing image processing is provided in the discussion section.

4.1. Adjust the raw data or input directory to match the formatting shown in **Figure 2**.

4.2. If time points are not contiguous (*i.e.*, T1, T2, T3), rename these folders so that they are. This step is critical to ensure that the *Image_Processing* macro does not crash during stacking.

4.3. Double-click on the Fiji icon to open the program, then click and drag the *Image_Processing* macro onto the Fiji bar. This will open the macro within Fiji.

4.4. Adjust lines 2-7 of the *Image_Processing* macro to specify the input directory containing images, the desired output directory for stitched and stacked images, the number of imaging timepoints, number of fluorescent channels and plate format.

4.5. Determine the order in which the images were acquired. To test this, manually stitch a montage of images in FIJI by maneuvering to the **Plugins** drop down menu | **Stitching** | **Grid/Collection stitching**. Adjust the settings within the dropdown menus **Type** and **Order** until an accurately stitched image is produced.

4.6. Adjust the **GRID_TYPE** and **STITCH_ORDER** variables in lines 8 and 9 of the *Image_Processing* macro to match these selections.

4.7. Specify the number of images per well by adjusting line 10 in the *Image_Processing* macro.

NOTE: For a 2 x 2 montage of images, this line would read DIM = 2.

4.8. If background subtraction is required, adjust line 14 in the *Image_Processing* macro to BGSUB = true.

4.9. Set the rolling ball radius by adjusting line 15 in the *Image_Processing* macro.

NOTE: For optimal results, set the radius to at least the diameter of the largest foreground object in the image.

4.10. Click **Run** to start the *Image_Processing* macro. Once started, *Image_Processing* will automatically advance through stitching, stacking, and background subtraction.

5. Scoring Cell Death

NOTE: See the **Discussion** section for more information on scoring cell death and censoring data.

5.1. Locate the image stacks produced by the *Image_Processing* script. Open these in FIJI.

5.2. Use the **point tool** within FIJI to individually label each cell with a number. Pressing **t** after each point will add the cell identifier to the ROI (region-of-interest) Manager.

NOTE: The identifiers can be visualized by clicking the **labels** and **show all** checkboxes in the ROI Manager.

5.3. Progress through the timepoints in each image stack and record the timepoint when each cell either dies or needs to be censored in the file *Survival_spreadsheet.csv* (see **Supplemental File 3**).

5.3.1. Each cell occupies a single row in the spreadsheet, where a unique identifier (ID) for each cell consists of its corresponding well and ROI number within that well. *tp_death* is the last time point a cell is observed to be alive, while *time_death* represents the actual time of death in hours. For each cell, input these data. It is critical to maintain this structure for subsequent analysis using *survival.R* (see **Supplemental File 4**).

NOTE: The criteria for determining cell death are crucial and may vary depending on cell type. Three main criteria are used in the identification of dead neurons^{11,20} (**Figure 3**): loss of fluorescence intensity (*e.g.*, Neuron 1 at 69 h), rounding of the cell body (*e.g.*, Neuron 2 at 188 h), and the loss of neurite integrity or blebbing (*e.g.*, Neuron 2 at 188 h).

5.4. Record the censor status of the cell in the last column.

NOTE: Here, due to the peculiar way censoring is handled by R, censored cells are marked by **0**, while uncensored cells are marked by **1**. Note that all cells that live to the last time point are censored, and therefore marked as **0**.

6. Performing Cox Proportional Hazards Analysis and Visualizing Results

6.1. If necessary, download R studio at <https://cran.r-project.org/mirrors.html>.

6.2. Open R studio and double-click the icon for the *survival.R* script.

6.3. Place the cursor on line 2 of *survival.R* and click the **run** button in the main R studio window in order to load the survival library.

6.4. Change line 5 of the *survival.R* script to match the location of the file *Survival_spreadsheet.csv*. Click on **run** to load the survival data as a dataframe.

6.5. Highlight lines 8 and 9 and click the **run** button in the R studio console window in order to perform Cox proportional hazards analysis. Results and output statistics appear in the console window of R studio.

6.6. Highlight lines 12-16 of *survival.R* and hit the **run** button in order to produce a cumulative risk of death plot, which will appear in the plots tab in R studio. This file can be saved by clicking on the **export** button above the plot.

6.7. If it is desirable to plot the survival data as a Kaplan-Meier curve, highlight lines 19-24 of *survival.R* and hit the **run** button.

REPRESENTATIVE RESULTS:

Using the transfection procedure described here, DIV4 rat cortical neurons were transfected with a plasmid encoding the fluorescent protein mApple. Beginning 24 h post-transfection, cells were imaged by fluorescence microscopy every 24 h for 10 consecutive days. The resultant images were organized as indicated in **Figure 2**, then stitched, stacked, and scored for cell death (**Figure 1**). **Figure 3** shows a time course for 3 representative neurons, two of which die during the course of the experiment (Neurons 1 and 2) while the third survives (Neuron 3).

Survival data were analyzed using the R script provided (*survival.R*), and the results summarized in **Figure 4**. The table generated upon running lines 7 and 8 of the *survival.R* code provides a summary of the Cox proportional hazards analysis. Four particularly important statistics in the table are highlighted in **Figure 4A**. The number in **Box 1** represents the hazard ratio for the group “Mutant” relative to “WT”. Notice that the “WT” group is not listed. This is because the “WT” group serves as the reference population — the risk of death observed in all other groups is compared to that of the reference population to calculate the hazard ratio. Therefore, hazard ratios greater than 1 indicate a faster rate of death in comparison to the reference population, and values less than 1 represent a reduced rate of death. In the example provided, mutant cells display a hazard ratio of 2.2, meaning that they died 2.2x faster than WT cells. By default, R will arrange the groups in alphanumeric order, with the top group serving as the reference population. Placing numbers in front of group names is an easy way to establish the order in which they are evaluated. The values in **Boxes 2** and **3** represent the p-values and 95% confidence intervals for the hazard ratios, respectively, calculated by Cox proportional hazards analysis. In **Box 4**, the results of the log-rank test are reported. This test evaluates whether there is a statistically significant difference in survival among populations being tested, but does not describe which groups are different from the others, and does not calculate a magnitude for the observed difference.

Kaplan-Meier curves (**Figure 4B**) are widely used in clinical trials for evaluating the effects of an intervention on patient survival. For this reason, many researchers are familiar with interpreting survival data visualized this way. In the context of single-cell survival, these plots depict the fraction of cells alive over time in each group. Rather than plotting cell survival, an alternative approach is to depict the rate of cell death in each group *via* a cumulative risk of death plot (**Figure 4C**). In most survival studies, the number of events does not follow a linear

progression; rather, for a given rate of death a greater number of events is observed at earlier times. For example, in a population of 100 cells, if 20% of cells die between intervals, then 20 cells will die within the first interval, 16 during the second interval, 13 during the third interval, and so on. This logarithmic trend is conceptually easier to visualize using cumulative risk of death plots, since the y-axis represents the negative log transform of cellular survival. Alternatively, the y-axis of the cumulative risk of death plot can also be presented as % cell death, calculated as $1 - 1/e^{\text{cumulative risk of death}}$. These plots also enable straightforward comparisons of the risk of death between populations. The magnitude of the hazard ratio reflects the slope of the cumulative risk of death plot for each population, relative to that of the reference group.

FIGURE AND TABLE LEGENDS:

Figure 1: Schema for a typical survival experiment. Rat cortical neurons are transfected at DIV4 using the procedure outlined in this article. Beginning 24 h post-transfection, cells are imaged at regularly spaced intervals in accordance with the specific requirements of the experiment. Images are stitched and stacked before cell death is scored, and Cox proportional hazard analysis is used to compare the risk of death between populations.

Figure 2: Required file structure. The provided FIJI macro requires that the raw data are formatted in a specific way. To utilize *Image_Processing*, organize the raw data as shown on the left. An example experiment and accompanying file structure is shown on the right.

Figure 3: Scoring cell death in transfected rat cortical neurons. Using the methods described in this article, rat cortical neurons were transfected with a plasmid encoding the fluorescent protein mApple. Cells were then imaged approximately every 24 h, the images were stitched and stacked, and cell death scored using the criteria provided. Cell death is indicated for Neuron 1 at 69 h, as evidenced by loss of fluorescence. Neuron 2 dies at 188 h, as indicated by fragmentation of the processes and rounding of the cell body. Neuron 3 survives for the duration of the experiment. Note that some cells become visible only late in the experiment, as evidenced by the appearance of a new cell at 235 h. Only cells that are visible at the initial time of imaging are included within subsequent analyses. Scale bar = 50 μm .

Figure 4: Interpretation of Cox proportional hazard analysis. (A) The output summary includes four important statistics that are highlighted in this figure. **Box 1** includes the hazard ratio of the experimental group relative to the control group, while **Box 2** and **Box 3** show the p-values and 95% confidence interval for each hazard ratio, respectively. **Box 4** highlights the results of the log-rank test. These data are also depicted *via* a Kaplan-Meier curve **(B)** and a cumulative risk of death plot **(C)**.

DISCUSSION:

Here, methodology to directly monitor neuronal survival on a single-cell basis is presented. In contrast to traditional assays for cell death that are limited to discrete time points and entire populations of cells, this method allows for the continuous assessment of a variety of factors

such as cellular morphology, protein expression, or localization, and can determine how each factor influences cellular survival in a prospective manner.

This methodology can be modified to fit a wide array of experimental needs. The frequency and duration of imaging can be easily adjusted, and any protein of interest can be co-transfected with the fluorescent marker to model disease states or investigate protein function¹³⁻¹⁹. Though this article describes the optimal procedure for transfecting rat cortical neurons, the experimental schema may be applied to any post-mitotic cell type. However, the optimal transfection conditions may need to be optimized on a per-cell line basis, and substrates may need to be adjusted to prevent cells from clumping or moving too much to reliably track.

Image processing and analysis requirements will vary depending on the specific parameters of each longitudinal microscopy experiment. A brief explanation of each critical step is included below to help customize the protocol to better match an experiment's demands.

Stitching: If a montage of images is taken, stitching can be performed to create a single, larger image for each field of view. For most applications it is preferable to perform stitching prior to stacking. If only one image is taken per well, there is no need to perform this step.

Stacking: Rather than tracking cells over time across separate image files, stacking can be performed to align consecutive images into a single time series, analogous to a stop frame animation. With successful fiduciary alignment, the individual frames comprising the stacked image will be closely aligned. However, if there are noticeable shifts or rotations between frames, image registration is needed. The *Image_Processing* macro automatically performs registration using the FIJI plugin "MultiStackReg." This plugin helps reduce small misalignments between imaging runs. However, with significant shifts, manually cropping and realigning images may be required.

Background subtraction (optional): One potential issue that may arise during image acquisition is uneven illumination. This will result in variations in signal intensity across an image that can confound estimates of fluorescence intensity. In these instances, intensity variations can be eliminated by background subtraction techniques. These are particularly relevant with low signal to noise ratios, where intensity shifts due to uneven illumination can be comparable in magnitude to the signal of the fluorophore itself. There are many background subtraction algorithms, several of which have associated FIJI plugins. The choice of which algorithm to use depends on the properties of the image itself and the signal being measured. Within the FIJI macro *Image_Processing*, the user is given the option to perform "rolling ball" background subtraction on a stacked set of images (line 14). In this method, a local background is determined for every pixel based on the average intensity of a circle surrounding that pixel. This value is then subtracted from the pixel's initial value. The optimal value for the radius of the circle used for local background estimates will differ based upon the diameter of the largest foreground object in the image.

Scoring cell death: For accurate comparisons between populations, it is essential that the criteria outlined above to identify dead neurons be applied consistently across the entire dataset. Furthermore, blinding the individuals scoring cell death to the experimental groups under investigation eliminates potential sources of bias. Depending on the specific criteria and their generalizability, they may be incorporated into automated algorithms for the unbiased assessment of cellular survival¹⁵⁻¹⁹.

In the context of survival analysis and other time-to-event analyses, there are three possible outcomes. First, the event (cell death) has occurred, and the time at which the event occurred is recorded. Second, the event did not occur during the time frame of observation. These observations are censored at the completion of the experiment. Third, the event could not be scored because the cell moved out of the field of view, or was obscured by nearby cells. In this case, the cell is censored when it can no longer be accurately tracked. For the first outcome, the precise timing of cell death may be difficult to determine based on the imaging interval. For instance, a cell that is alive initially but marked as dead 24 h later may have died at any point within that 24 hour period. To be conservative, it is good practice to record the time of death as the last time a cell can be confidently identified as alive (left censoring).

Performing Cox proportional hazards analysis and visualizing results: The accompanying *Survival.R* script enables the comparison of risk of death among populations and their statistical significance using Cox proportional hazards analysis (**Figure 4A**), and also plot results as either a Kaplan-Meier curve (**Figure 4B**) or a cumulative risk of death plot (**Figure 4C**). Survival analysis, Cox proportional hazards analysis, and the “survival” package in R are described in more detail by Christensen¹² and at <https://cran.r-project.org/web/packages/survival/survival.pdf>.

By adapting the procedures outlined here, a variety of neuronal features can be related to survival. Generation of an ROI around the cell body and/or nucleus enables the user to longitudinally monitor cell size and morphology, protein expression level and localization, or the formation of subcellular structures such as puncta or protein aggregates¹³⁻¹⁹. Importantly, because each of these factors is observed in relation to cell death, it is possible to quantitatively determine how well individual factors predict cellular survival or death during the given time frame. Protein metabolism and cellular pathways may also be assayed by expressing fluorescent reporters that provide real-time measurements of underlying cellular physiology (e.g., gCaMP6f to assay activity). By employing this powerful approach, factors that drive cellular maintenance, function, and dysfunction can be uncovered and studied in detail, thereby inspiring new avenues of inquiry.

ACKNOWLEDGEMENTS:

We thank Steve Finkbeiner and members of the Finkbeiner lab for pioneering robotic microscopy. We also thank Dan Peisach for building the initial software required for image processing and automated survival analysis. This work was funded by the National Institute for Neurological Disorders and Stroke (NINDS) R01-NS097542, the University of Michigan Protein Folding Disease Initiative, and Ann Arbor Active Against ALS.

DISCLOSURES:


The authors have nothing to disclose.

REFERENCES:

1. Lockshin, R. A., Zakeri, Z. Cell death in health and disease. *Journal of Cellular and Molecular Medicine*. **11**, 1214-1224 (2007).
2. Kepp, O., Galluzzi, L., Lipinski, M., Yuan, J., Kroemer, G. Cell death assays for drug discovery. *Nature Reviews Drug Discovery*. **10**, 221-237 (2011).
3. Lemasters, J. J. *et al.* The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. *Biochimica et Biophysica Acta Bioenergetics*. **1366**, 177-196 (1998).
4. Vermes, I., Haanen, C., Steffens-Nakken, H., Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. *Journal of Immunological Methods*. **184**, 39-51 (1995).
5. Chien, K. R., Abrams, J., Serroni, A., Martin, J. T., Farber, J. L. Accelerated phospholipid degradation and associated membrane dysfunction in irreversible, ischemic liver cell injury. *Journal of Biological Chemistry*. **253**, 4809-4817 (1978).
6. Zwaal, R. F. A., Comfurius, P., Bevers, E. M. Surface exposure of phosphatidylserine in pathological cells. *Cell and Molecular Life Sciences*. **62**, 971-988 (2005).
7. Mitchell, D. B., Santone, K. S., Acosta, D. Evaluation of cytotoxicity in cultured cells by enzyme leakage. *Journal of Tissue Culture Methods*. **6**, 113-116 (1980).
8. Moran, J. H., Schnellmann, R. G. A rapid beta-NADH-linked fluorescence assay for lactate dehydrogenase in cellular death. *Journal of Pharmacological and Toxicological Methods*. **36**, 41-44 (1996).
9. Mossman, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *Journal of Immunological Methods*. **65** (1-2), 55-63 (1983).
10. Guerzoni, L. P. B. *et al.* In Vitro Modulation of TrkB Receptor Signaling upon Sequential Delivery of Curcumin-DHA Loaded Carriers Towards Promoting Neuronal Survival. *Pharmaceutical Research*. **34** (2), 492-505 (2017).
11. Arrasate, M., Finkbeiner, S. Automated microscope system for determining factors that predict neuronal fate. *Proceedings of the National Academy of Science of the United States of America*. **102**, 3840-3845 (2005).
12. Christensen, E. Multivariate survival analysis using Cox's regression model. *Hepatology*. **7**, 1346-1358 (1987).
13. Barmada, S. J. *et al.* Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. *Nature Chemical Biology*. **10**, 677-685 (2014).
14. Barmada, S. J. *et al.* Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. *Proceedings of the National Academy of Science of the United States of America*. **112**, 7821-7826 (2015).
15. Malik, A. M. *et al.* Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and nucleocytoplasmic localization. *Elife*. **7**, (2018).
16. Archbold, H. C. *et al.* TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. *Scientific Reports*. **8**, 4606 (2018).

- 481 17. Green, K. M. *et al.* RAN translation at C9orf72-associated repeat expansions is
482 selectively enhanced by the integrated stress response. *Nature Communications*. **8**, 2005
483 (2017).
- 484 18. Park, S.-K. *et al.* Overexpression of the essential Sis1 chaperone reduces TDP-43 effects
485 on toxicity and proteolysis. *PLOS Genetics*. **13**, e1006805 (2017).
- 486 19. Gupta, R. *et al.* The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded
487 C9ORF72 Inhibits the Proteasome. *eNeuro*. **4**, (2017).
- 488 20. Angelov, B., Angelova, A. Nanoscale clustering of the neurotrophin receptor TrkB
489 revealed by super-resolution STED microscopy. *Nanoscale*. **9** (28), 9797-9804 (2017).

Figure 1




File Structure

Experiment name
└ Data folder
 └ One folder per channel
 └ One folder per time point
 └ One folder per column
 └ Raw images

Example

Experiment "Survival_Analysis_1" (2x2 montage of well A01 in the RFP channel for one time point) would be organized as follows:

Survival_Analysis_1
└ raw_images
 └ RFP
 └ T1
 └ col_01
 └ A01_1
 └ A01_2
 └ A01_3
 └ A01_4



A

```
Call:
coxph(formula = Surv(time_death, as.logical(censored)) ~ group,
      data = datofile)



n= 71, number of events= 61
```


	coef	exp(coef)	se(coef)	z	Pr(> z)
group2. Mutant	0.8148	2.2578	0.2681	3.13	0.00175 **

Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1

	exp(coef)	exp(-coef)	lower .95	upper .95
group2. Mutant	2.257	0.4431	1.356	3.758

Concordance= 0.65 (se = 0.045)
 Rsquare= 0.323 (max possible= 0.998)
 Likelihood ratio test= 9.36 on 1 df, p=0.00222
 Wald test = 9.8 on 1 df, p=0.001749
 Score (logrank) test = 10.31 on 1 df, p=0.001321






[Click here to access/download](#)

Video or Animated Figure

Supplemental File 2_Image_Processing.ijm







[Click here to access/download](#)

Video or Animated Figure

Supplemental File 3_Survival_spreadsheet.csv







[Click here to access/download](#)

Video or Animated Figure

Supplemental File 4_survival.R



Name of Material/ Equipment	Company
Neurobasal Medium	GIBCO
Opti-MEM	GIBCO
CompactPrep Plasmid Maxi Kit	Qiagen
Magnesium chloride Hexahydrate	Sigma
Kynurenic Acid Hydrate	TCI
Poly D-Lysine	Millipore
Glutamax	GIBCO
Lipofectamine 2000	Invitrogen
B27 supplement	Thermo Fisher
Penicillin Streptomycin	GIBCO
96 well plates	TPP

Catalog Number	Comments/Description
21103-049	
31985-070	
12863	
M9272	
H0303	
A-003-E	
35050-061	
52887	
A3582801	
15140122	
0876	



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Monitoring neuronal survival via longitudinal fluorescence microscopy

Author(s):

Kaitlin Weskamp, Nathaniel Safren, Roberto Miguez, Sami Barmada

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:	Sami Barmada	
Department:	Neurology	
Institution:	University of Michigan	
Title:	Assistant Professor	
Signature:		Date: 8/31/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

We thank the editor and reviewers for their comments and suggestions. Below, we list each of the comments in black, followed by our responses in blue.

Editorial comments:

Changes to be made by the Author(s) regarding the written manuscript:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.

We proofread the manuscript and removed all spelling and grammar errors.

2. Please provide an email address for each author.

Email addresses for each author are included in lines 6-9 of the revised manuscript.

3. Please rephrase the Short Abstract to clearly describe the protocol and its applications in complete sentences between 10-50 words: "Here, we present a protocol to ..."

The short abstract has been revised accordingly.

4. Please spell out each abbreviation the first time it is used.

All abbreviations are now explained upon initial usage.

5. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. You may use the generic term followed by "(see table of materials)" to draw the readers' attention to specific commercial names. Examples of commercial sounding language in your manuscript are: Optimem, Neurobasal, Lipofectamine, etc.

All references to company names have been removed from the revised manuscript.

6. Please include an ethics statement before your numbered protocol steps, indicating that the protocol follows the animal care guidelines of your institution.

An appropriate ethics statement now appears prior to the protocol within the revised manuscript.

7. Please revise the protocol text to avoid the use of any personal pronouns (e.g., "we", "you", "our" etc.).

All personal pronouns have been removed from the revised manuscript.

8. Please revise the protocol to contain only action items that direct the reader to do something (e.g., "Do this," "Ensure that," etc.). The actions should be described in the imperative tense in complete sentences wherever possible. Avoid usage of phrases such as "could be," "should be," and "would be" throughout the Protocol. Any text that cannot be written in the imperative tense may be added as a "Note." Please include all safety procedures and use of hoods, etc. However, notes should be used sparingly and actions should be described in the imperative tense wherever possible.

All auxiliary verbs such as "should", "could" and "would" have been removed from the revised manuscript and replaced by imperatives where possible.

9. Please add more details to your protocol steps. There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol. Please ensure you answer the "how" question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action. See examples below:

1.2: Please add more details here or provide a relevant reference. As currently written, it does not have enough details to replicate.

For this step, we now reference the protocol provided by plasmid purification kits.

3.3: How are the cells fluorescently labeled? Previous steps do not mention this.

In lines 61-63 of the revised manuscript, we state “longitudinal fluorescence microscopy involves the transient transfection or transduction of cells with vectors encoding fluorescent proteins.” Additionally, section 2.10 of the revised manuscript states “Successfully transfected cells should be visible by fluorescence microscopy within 16-24h of transfection. To gauge efficiency, use a fluorescent microscope to check the transfection after overnight incubation at 37 °C. This technique results in an overall transfection efficiency of 5 to 10%.”

3.4: Please give specific examples for appropriate channels/regularly-spaced intervals.

The particular channels and spacing utilized for this step depends on the application. To reflect this flexibility, section 3.4 has been revised as follows: “Take fluorescent images in the appropriate channel or channels (e.g. RFP, GFP, DAPI), either manually or in an automated manner. By taking several images at regularly-spaced intervals, a montage of the well can be assembled during image processing (see below). The spacing depends on several factors, including magnification, the optics of the microscope, and the detector size. In general, the optical spacing between adjacent images will be between 90-95% of the size of each individual image, to allow for a small degree of image overlap and feature alignment.”

10. Steps 4-6: The Protocol should be made up almost entirely of discrete steps without large paragraphs of text between sections and should contain only action items that direct the reader to do something. Please simplify the Protocol so that individual steps contain only 2-3 actions per step and a maximum of 4 sentences per step. Use sub-steps as necessary. Please move the results to the Representative Results and move discussion about the protocol to the Discussion.

The protocol has been streamlined as suggested.

11. Steps 4-6: Software must have a GUI (graphical user interface) and software steps must be more explicitly explained ('click', 'select', etc.). Please add more specific details (e.g. button clicks for software actions, numerical values for settings, etc.) to your protocol steps. There should be enough detail in each step to supplement the actions seen in the video so that viewers can easily replicate the protocol.

The Fiji program operates via a user-friendly GUI. Most of the image processing within Fiji occurs via the use of drop down menus, and where possible we indicated which menu to select and which item within each drop down menu to focus upon for the relevant step of the protocol. Adjustments to the macro itself require that users type in appropriate paths, as indicated within the protocol and Figure 2.

12. Please include single-line spaces between all paragraphs, headings, steps, etc.

The manuscript has been revised to include single-line spaces where indicated.

13. After you have made all the recommended changes to your protocol (listed above), please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol.

14. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense.

15. Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.

Sections 1-3 of the protocol, comprising (1) Material Preparation, (2) Transfection of rat primary cortical neurons, and (3) Imaging, have been highlighted within the revised manuscript. These sections include complete sentences with imperative tenses. All necessary details are contained within the highlighted text.

16. Figure 3: Please include a space between all numbers and their units (18 h, 44 h, 69 h, etc.).

Figure 3 has been revised to include spaces between each number and its unit.

17. Discussion: Please also discuss critical steps within the protocol and any limitations of the technique.

We revised the discussion section of the manuscript to include a list of critical steps that may have to be adjusted for each application accordingly. Limitations of the technique are embedded within the results and discussion sections.

18. Please revise the table of the essential supplies, reagents, and equipment to include the name, company, and catalog number of all relevant materials in separate columns in an xls/xlsx file.

The table of essential supplies has been revised accordingly.

19. References: Please do not abbreviate journal titles.

All abbreviations have been removed from the list of references.

Reviewers' comments:

Reviewer #1:

The paper is interesting but the current version sounds quite specialized.

Page 1: The following sentence needs to be improved in order to attract readers: "The requirement for static "snapshots" of separate populations of cells precludes the ability to discriminate whether an event is a disease driver, a homeostatic response, or merely coincidental."

To clarify this point further, we revised this section to read, "These assays require the observation of separate populations of cells at discrete time points. As a result, individual cells cannot be followed prospectively over time, severely limiting the ability to discriminate whether subcellular events, such as puncta formation or protein mislocalization, are pathogenic drivers of disease, homeostatic responses, or merely coincidental phenomena."

The title may read:

"Monitoring neuronal survival via single cell longitudinal fluorescence microscopy"

We thank the reviewer for their suggestion, and have change the title accordingly.

The terminology of robotic microscopy and the principal of longitudinal microscopy need to be introduced in more detail, e.g. by including a figure.

In writing this manuscript, we intentionally avoided the use of the term "robotic microscopy", since this more accurately describes sophisticated and autonomous platforms that include robotic means of plate transfer to and from the microscope, bar-coding of individual plates, and scheduling software enabling 24/7 experimentation. Instead, we focus on the ability of the method to longitudinally track individual, fluorescently labeled cells chronologically and prospectively, until their time of death. To better illustrate the principal of longitudinal fluorescence microscopy, we revised the introduction to include the following section:

"In brief, longitudinal fluorescence microscopy enables thousands of individual cells to be tracked at regular intervals for extended periods of time, allowing precise determinations of cell death and the factors that

enhance or suppress cell death. At its base, the method involves the transient transfection or transduction of cells with vectors encoding fluorescent proteins. A unique fiduciary is then established, and the position of each transfected cell in relation to this landmark allows the user to image and track individual cells over the course of hours, days, or weeks. When these images are viewed sequentially, cell death is marked by characteristic changes in fluorescence, morphology, and fragmentation of the cell body, enabling the assignment of a time of death for each cell. The calculated rate of death, determined by the hazard function, can then be quantitatively compared between conditions, or related to select cellular characteristics using univariate or multivariate Cox proportional hazards analysis¹⁰. Together, these approaches enable the accurate and objective discrimination of rates of cell death among cellular populations, and the identification of variables that significantly predict cell death and/or survival (Figure 1)."

We also revised figure 1 to include images from a representative experiment, thereby solidifying the general concept of longitudinal microscopy discussed above and subsequently in the text of the manuscript.

Page 2. Lines 52-53: "Microscopy" is a method. Therefore, it cannot be considered as "a flexible system".

We revised this line to read "In contrast, longitudinal fluorescence microscopy is a highly flexible methodology that directly and continuously monitors the risk of death on a single-cell basis⁹."

The Introduction should include broader references about the neuronal survival:

- Pharm. Res. 2017, 34, 492-505, DOI: 10.1007/s11095-016-2080-4 ;
- Nanoscale, 2017, 9, 9797-9804. DOI: 10.1039/C7NR03454G.

We thank the reviewer for highlighting these two papers, which we now refer to in the introduction and protocol sections. In the introduction section of the revised manuscript, we cite both the *Pharmaceutical Research* paper as well as the original article outlining the MTT assay. The *Nanoscale* paper referenced by the reviewer discusses morphological criteria for gauging neuronal survival, similar to those that we outline in step 5.3.1 of the protocol. As such, we also reference the *Nanoscale* work within this section of the revised manuscript.

The current Figure 1 is not comprehensive enough. It should illustrate also the biological protocol: "24 h post-transfection, cells were imaged by fluorescence microscopy every 24 h for 10 consecutive days".

While we understand the reviewers point, we remain concerned that labeling the figure with such discrete time points will suggest that this is the only way to organize the experiment. In contrast, we wish to emphasize to readers the flexibility of the timing interval—depending on the application or the experiment, the interval could range from a few ms to a few days, and the number of time points could be anywhere from 1 – 1000 or more. Therefore, we intentionally avoided labeling the time points in Figure 1 with predefined intervals.

To address the reviewers point, the first paragraph of the Representative Results section includes the following statements:

"Using the transfection procedure described here, DIV4 rat cortical neurons were transfected with a plasmid encoding the fluorescent protein mApple. 24 h post-transfection, cells were imaged by fluorescence microscopy every 24 h for 10 consecutive days."

Additionally, the legend to figure 1 states:

"Rat cortical neurons are transfected at DIV4 using the procedure outlined in this article. Beginning 24 h post-transfection, cells are imaged at regularly spaced intervals in accordance with the specific requirements of the experiment. Images are stitched and stacked before cell death is scored, and Cox proportional hazard analysis is used to compare the risk of death between populations."

The paragraph about the statistics should be included with the section Representative results. The text should account for the given descriptions

"For example, in a population of 100 cells, if 20% of cells die between intervals, then 20 cells will die within the first interval, 16 during the second interval, 13 during the third interval, and so on. This

logarithmic trend is conceptually easier to visualize using cumulative risk of death plots, since the y-axis represents the negative log transform of cellular survival."

We thank the reviewer for this suggestion, and in the revised manuscript moved the description of statistics to the Representative Results section.

Reviewer #2:

Manuscript Summary:

In this article Westcamp et al. describe a method to longitudinally follow post mitotic cells and monitor their survival through imaging and analysis on an individual cell basis. This individual cell tracking allows for a detailed analysis of cell death within a population in which cells from the same culture may undergo death at different times, yielding finer detail than other methods that pool all cells for a bulk population readout. Cells - in this example primary cortical neurons - are transiently transfected with a fluorescent marker, and plates are longitudinally imaged from a reference point. In doing so the authors are able to track individual cells and can identify the time point of their death or disappearance. Moreover, this method allows for the examination of specific cellular phenotypes detectable via imaging that may be predictive of cell death, which is particularly interesting and may be scaled up for relatively high-throughput application. The authors provided a detailed and clear explanation of the method as well as the analysis pipeline. Additionally, the authors have used Image J for most of their analysis, making it straightforward for others to implement this technique. Overall the article is very clear and well written and should be useful to others hoping to implement this method.

Major Concerns:

None.

Minor Concerns:

In Figure 3 at the 235 hour time point, there seems to be a new cell that appears in the middle left. They authors could comment on how to track cells that may migrate slightly.

The reviewer brings up two good points. First, cells that move or migrate out of the field of view, and therefore cannot be scored for cell death accurately, are typically censored. This possibility is discussed in lines 1087-1095 of the revised manuscript:

"In the context of survival analysis and other time-to-event analyses, there are three possible outcomes:

- 1) The event (cell death) has occurred, and the time at which the event occurred is recorded.
- 2) The event did not occur during the time frame of observation. These observations are censored at the completion of the experiment.
- 3) The event could not be scored because the cell moved out of the field of view, or was obscured by nearby cells. In this case, the cell is censored when it can no longer be accurately tracked."

Second, the cell identified by the reviewer does not actually move, but instead exhibits a dramatic increase in fluorescence relatively late in the experiment. If the cell cannot be accurately identified at the initial imaging time point, it cannot be followed prospectively. This eventuality is described within the revised legend of figure 3:

"Figure 3. Scoring cell death in transfected rat cortical neurons. Using the methods described in this article, rat cortical neurons were transfected with a plasmid encoding the fluorescent protein mApple. Cells were then imaged approximately every 24 h, the images were stitched and stacked, and cell death scored using the criteria provided. Cell death is indicated for Neuron 1 at 69 h, as evidenced by loss of fluorescence. Neuron 2 dies at 188 h, as indicated by fragmentation of the processes and rounding of the cell body. Neuron 3 survives for the duration of the experiment. Note that some cells become visible only late in the experiment, as evidenced by the appearance of a new cell at 235 h. Only cells that are visible at the initial time of imaging are included within subsequent analyses. Scale bar = 50 μ m."

Experiment NameExperiment datePlate type

ExampleMM/DD/YYYY96wChoices: 96w, 48w, 24w, 12w, 6w

DNA plate map	1	2	3	4	5	6	7	8	9	10	11	12
A	DNA A	DNA A	DNA A	DNA A	DNA A	DNA A	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C
B	DNA A	DNA A	DNA A	DNA A	DNA A	DNA A	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C
C	DNA A	DNA A	DNA A	DNA A	DNA A	DNA A	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C
D	DNA A	DNA A	DNA A	DNA A	DNA A	DNA A	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C
E	DNA A	DNA A	DNA A	DNA A	DNA A	DNA A	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C
F	DNA A	DNA A	DNA A	DNA A	DNA A	DNA A	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C
G	DNA A	DNA A	DNA A	DNA A	DNA A	DNA A	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C
H	DNA A	DNA A	DNA A	DNA A	DNA A	DNA A	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C	DNA B + DNA C

DNA A		Concentration (µg/mL)	1.3
Plate type:			96
Number of different DNAs			1
Number of wells for DNA A			48
OptiMEM for DNA and lipofectamine (each)			1320.00
Lipofectamine			24.00
DNA:Lipofectamine mix (total)			2400.00
Volume of DNA:Lipofectamine mix per well			50.00
		µg/well	[DNA]
DNA A	0.20	1.3	8.12

DNA B		Concentration (µg/mL)	1.2
DNA C		Concentration (µg/mL)	1.1
Plate type:			96
Number of different DNAs			2
Number of wells for DNA B + DNA C			48
OptiMEM			1320.00
Lipofectamine			24.00
DNA:Lipofectamine mix (total)			2400.00
Volume of DNA:Lipofectamine mix per well			50.00
		µg/well	[DNA]
DNA B	0.10	1.2	4.40
DNA C	0.10	1.1	4.80